Endometriosis has been documented since at least 1690, when physician Daniel Shroen described lesions on the peritoneum and bowel during post-mortem examination, and was formally named and characterised by John Sampson in 1927, who proposed the theory of retrograde menstruation that remains one of the dominant — if incomplete — explanatory frameworks for its pathogenesis. It affects an estimated 190 million individuals of reproductive age worldwide — approximately one in ten women of reproductive age in most population studies, rising to one in two in populations with infertility — and yet despite this prevalence, its median diagnostic delay, measured across multiple countries and healthcare systems, is between seven and ten years. In the United Kingdom, a study published in the British Journal of General Practice found an average delay of 7.5 years. In Australia, 6.4 years. In the United States, studies consistently report delays exceeding 9 years, with some reaching 11. These numbers have not substantially improved in a generation. During those lost years, endometriotic lesions continue to grow, infiltrate, and generate inflammatory cascades. Ovarian endometriomas expand. Rectovaginal and bowel lesions deepen. Adhesions fuse pelvic organs. Nerves are invaded. Fertility may be lost. The patient is told, at every step, that what she is experiencing is within the spectrum of normal.
The diagnostic delay in endometriosis is not a consequence of the disease being rare or diagnostically inaccessible. Endometriosis produces symptoms that are sufficiently characteristic to generate clinical suspicion in the hands of a trained generalist, sufficiently specific to justify imaging and specialist referral in early disease, and definitively diagnosable on laparoscopy with histological confirmation of excised lesions. The delay exists because the symptoms — primarily severe pelvic pain with menstruation — are culturally normalised in women, because the condition has historically received a fraction of the research funding allocated to conditions of equivalent prevalence in other populations, and because the medical training that produces the generalists who are the first clinical contact for the majority of patients with endometriosis does not yet include endometriosis as a standard differential in the clinical curriculum with the prominence it deserves. The delay is not biological. It is institutional.
What Endometriosis Is — The Biology Before the Pathology
The normal endometrium is a dynamic tissue: a glandular and stromal lining that proliferates under oestrogen stimulation in the follicular phase of the menstrual cycle, differentiates under progesterone stimulation after ovulation, and — in the absence of implantation — undergoes apoptosis and shedding at menstruation, accompanied by coordinated local prostaglandin-mediated uterine contractions that expel the menstrual effluent. In endometriosis, this tissue — or tissue with its functional and histological characteristics — exists outside the uterine cavity. The precise mechanism by which it arrives there is the subject of ongoing research and significant scientific controversy, because no single theory adequately explains all forms of the disease.
The retrograde menstruation theory, proposed by Sampson, holds that menstrual effluent containing viable endometrial cells refluxes through the fallopian tubes into the peritoneal cavity during menstruation, and that these cells implant on peritoneal surfaces, the ovaries, and pelvic structures. Evidence supporting this theory includes the observation that retrograde menstruation occurs in approximately 90% of women with patent fallopian tubes, that endometriosis is more common on the left side of the pelvis (consistent with the direction of retrograde flow), and that women with outflow obstruction have higher rates of endometriosis. However, it fails to explain extra-pelvic endometriosis — lesions on the diaphragm, pleura, pericardium, and brain — or why only 10–15% of women with retrograde menstruation develop endometriosis rather than all of them. These limitations point to additional factors: immune dysregulation that normally eliminates ectopic endometrial cells but fails to do so in women with endometriosis, and genetic predisposition that modulates susceptibility.
The coelomic metaplasia theory proposes that the peritoneum and müllerian remnants retain the capacity to differentiate into endometrial-like tissue under hormonal or environmental stimulation — a mechanism that could explain peritoneal and bowel endometriosis without requiring retrograde menstruation and that would explain endometriosis in women with no functional endometrium and in rare reported male cases following oestrogen therapy. The embryonic rest theory suggests that displaced müllerian remnants left during fetal development give rise to endometriotic lesions in extra-pelvic locations. Lymphatic and haematogenous dissemination of endometrial cells explains distant endometriosis in the thoracic cavity (catamenial pneumothorax), liver, and peripheral anatomical sites. The complete pathogenesis of endometriosis is almost certainly a combination of these mechanisms operating in different subtypes and anatomical distributions of the disease, modified by individual genetic susceptibility, immune function, and hormonal milieu.
Why endometriosis lesions produce pain disproportionate to their visible size
One of the most clinically important and most commonly misunderstood features of endometriosis is the poor correlation between the extent of visible disease at surgery and the severity of pain. A patient with Stage I endometriosis — small peritoneal lesions with no adhesions, no ovarian involvement, classified as minimal — may have the most severe, disabling pain in the clinic. A patient with Stage IV disease — dense adhesions, bilateral endometriomas, partial bowel involvement — may have significantly less pain until the disease affects a particularly pain-sensitive structure. This paradox is not a reflection of patient exaggeration at the mild end or of high pain tolerance at the severe end. It is a reflection of the biology of endometriotic lesion-induced neurogenesis, central sensitisation, and the distinct pain mechanisms of peritoneal versus deep infiltrating versus ovarian endometriosis.
Peritoneal endometriosis lesions, even when small, produce a local inflammatory environment characterised by elevated concentrations of prostaglandin E2 (PGE2), prostaglandin F2-alpha (PGF2α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF). These mediators sensitise the peritoneal sensory nerve fibres — the pelvic afferents that transmit pain signals to the spinal cord — lowering their activation threshold and recruiting previously silent nociceptors to fire in response to stimuli that would not normally produce pain. Critically, active endometriotic lesions also produce nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which stimulate the growth of new sensory nerve fibres directly into the lesion tissue — a process of lesion innervation that creates a direct structural connection between the endometriotic implant and the peripheral pain signalling system. The innervated lesion is not merely near a nerve; the nerve grows into it, and the inflammatory mediators within it directly depolarise the embedded nerve terminals with every cycle. This is why small, active peritoneal lesions can produce severe pain. The lesion is not the size of the problem. The lesion is the generator of the neurobiological problem, which is the sensitisation.
The Three Anatomical Subtypes — Peritoneal, Ovarian, and Deep Infiltrating
Endometriosis is not a single lesion type in a single anatomical location. It is a family of disease presentations that share the common biology of ectopic endometrial-like tissue but differ profoundly in their anatomical distribution, their relationship to adjacent structures, the mechanisms by which they produce symptoms, the imaging modalities that detect them, and the surgical complexity required to excise them completely. Treating all three subtypes with the same surgical or medical approach is one of the commonest sources of inadequate management and persistent post-operative symptoms.
Superficial Peritoneal Endometriosis
Superficial peritoneal endometriosis (also called minimal or mild endometriosis in the revised ASRM staging system) describes endometriotic lesions implanted on the pelvic peritoneum — the thin serous membrane lining the pelvic cavity and covering pelvic organs. Lesions appear in multiple morphological forms: the classic "powder burn" or black lesion, representing haemosiderin-laden macrophages from repeated cyclical bleeding, is the most recognisable; but atypical lesions — clear vesicular lesions, red flame-shaped lesions (which are the most metabolically active and most pro-inflammatory), white fibrotic plaques, and subtle surface irregularities — are equally or more prevalent and are far more commonly missed at laparoscopy by surgeons without specialist training. Red lesions in particular have been shown to have significantly higher prostaglandin production and nerve fibre density than black lesions, making them the most pain-productive morphological type. Superficial peritoneal lesions do not infiltrate deeper than 5mm by definition; deep lesions are classified separately. They are commonly found in the pouch of Douglas (the rectouterine space), the uterosacral ligaments, the posterior broad ligament, the ovarian fossae, and the anterior cul-de-sac. Despite being "superficial," these lesions can cause severe dysmenorrhoea and pelvic pain through the neuro-inflammatory mechanisms described above, and complete peritoneal excision — removing all visible lesion tissue — is the surgical standard that produces superior pain outcomes compared to ablation (burning or vaporising lesion surfaces).
Ovarian Endometriosis (Endometrioma)
Ovarian endometriosis — the endometrioma or "chocolate cyst" — develops when endometriotic tissue implants on the ovarian surface and invaginates into the ovarian cortex, forming a cystic structure lined by endometriotic epithelium that fills with thick, dark, haemolysed blood resembling melted chocolate (giving rise to the colloquial name). Endometriomas are reliably detected on transvaginal ultrasound (tvUS) by characteristic features: homogeneous low-level echogenicity ("ground glass" appearance), absence of papillary projections in benign cases, and typical location within the ovarian substance. MRI provides superior tissue characterisation when the diagnosis is uncertain or when associated deep infiltrating endometriosis is suspected. Endometriomas cause symptoms through several mechanisms: direct inflammatory effect of the cyst contents on adjacent pelvic structures; compression and inflammation of the ovarian cortex, which houses the primordial follicle pool — the ovarian reserve; and recruitment of iron-mediated reactive oxygen species (ROS) into the ovarian microenvironment from the haemosiderin-rich cyst contents, causing oxidative damage to oocytes in adjacent follicles. This oxidative mechanism is responsible for the significantly reduced ovarian reserve (as measured by anti-Müllerian hormone, AMH) documented in women with endometriomas compared to age-matched controls without the disease, and for the accelerated follicle loss that occurs both from the endometrioma itself and — critically — from surgical drainage or incomplete excision that fails to remove the cyst wall entirely. The management of endometriomas in women desiring fertility requires meticulous surgical decision-making, balancing the benefits of complete cyst wall excision (preventing recurrence, reducing inflammatory damage) against the risk of inadvertent removal of adjacent normal ovarian cortex.
Deep Infiltrating Endometriosis (DIE)
Deep infiltrating endometriosis (DIE) is defined as endometriotic tissue penetrating more than 5mm below the peritoneal surface, invading the muscularis propria of organs and the subperitoneal space. DIE is the most surgically complex and the most symptomatic form of endometriosis, producing a specific and characteristic symptom constellation that closely maps to the organs infiltrated: the uterosacral ligaments, the rectovaginal septum, the rectosigmoid colon and small bowel, the bladder and ureters, the vaginal fornix, and — in severe cases — the diaphragm, appendix, and pelvic sidewall. The posterior compartment is the most commonly affected: rectovaginal nodules and bowel endometriosis are found in up to 25–35% of women with severe disease. Bowel DIE produces cyclical catamenial diarrhoea, constipation, rectal bleeding, dyschezia (painful defaecation), and tenesmus (the sensation of incomplete rectal emptying after defaecation) — symptoms that are frequently attributed to irritable bowel syndrome for years before the pelvic origin is identified. Ureteric DIE can produce extrinsic ureteric compression resulting in hydroureter and hydronephrosis — a "silent" complication that causes progressive renal damage without pain, making regular renal tract imaging mandatory in women with known posterior compartment DIE. Complete surgical excision of DIE nodules — including disc excision or segmental bowel resection for deep bowel involvement — is the definitive treatment, requires multi-disciplinary surgical teams (gynaecologist plus colorectal or urological surgeon), and should only be performed at accredited centres with the appropriate surgical volume and expertise to perform these procedures safely. It is not a procedure for the general gynaecology operating list.
Adenomyosis — Endometriosis of the Myometrium
Adenomyosis — the presence of endometrial glands and stroma within the myometrium (uterine muscle), surrounded by reactive smooth muscle hypertrophy — is a distinct but frequently co-occurring and pathogenically related condition to pelvic endometriosis. Historically diagnosed only on pathological examination of hysterectomy specimens, adenomyosis is now detectable with reasonable accuracy on transvaginal ultrasound (myometrial heterogeneity, asymmetric myometrial thickening, irregular junctional zone, myometrial cysts, fan-shaped acoustic shadowing) and with superior sensitivity on MRI (junctional zone thickness above 12mm on T2-weighted imaging, junctional zone ratio above 0.40, poor definition of the junctional zone). Adenomyosis produces severe, progressive dysmenorrhoea and heavy menstrual bleeding (HMB) that is frequently disproportionate to the degree of uterine enlargement, because the embedded endometrial glands bleed with each cycle within the myometrium, causing uterine oedema, PGE2-driven uterine hypercontractility, and — in focal adenomyosis — the development of adenomyomas that distort the uterine cavity. Adenomyosis co-exists with pelvic endometriosis in an estimated 30–50% of cases; its presence significantly affects both the symptom burden and the surgical planning for endometriosis management. Unlike pelvic endometriosis, adenomyosis does not have a definitive non-hysterectomy surgical solution in most cases — management is primarily hormonal (levonorgestrel-releasing intrauterine system, progestin-dominant oral contraceptives, GnRH analogues) with uterine-sparing surgical options (adenomyomectomy, uterine artery embolisation, high-intensity focused ultrasound/HIFU) available in selected cases.
Extra-Pelvic and Thoracic Endometriosis
Extra-pelvic endometriosis encompasses all disease outside the pelvic cavity — a category that is rare but produces clinical presentations that are frequently unrecognised and attributed to entirely separate pathologies. Thoracic endometriosis syndrome (TES) includes catamenial pneumothorax (cyclical collapsed lung occurring within 72 hours of menstruation, caused by diaphragmatic endometriotic lesions allowing air passage into the pleural space), catamenial haemothorax, catamenial haemoptysis (cyclical coughing of blood), and pulmonary parenchymal endometriosis. Any woman of reproductive age with a pneumothorax occurring within 24–72 hours of menstruation should be evaluated for thoracic endometriosis before being managed with standard pneumothorax protocols — the recurrence rate with standard management is near-certain without hormonal suppression and, in definitive cases, thoracoscopic surgical excision of diaphragmatic lesions. Umbilical endometriosis (Villar's nodule) produces a painful, palpable, cyclically enlarging umbilical mass that bleeds with menstruation — its appearance is characteristic but it is frequently excised as a sebaceous cyst or umbilical hernia without recognition of the endometriotic aetiology, precluding appropriate subsequent management. Scar endometriosis — implantation of endometriotic tissue in surgical scar tissue, most commonly caesarean section scars — produces a painful, enlarging, cyclically tender mass at the scar site and is consistently misdiagnosed as keloid, suture granuloma, or desmoid tumour. Sciatic nerve endometriosis, perineural endometriosis of the pudendal nerve, and obturator nerve endometriosis produce cyclical catamenial radiculopathy — pain, weakness, and sensory changes in a nerve distribution that worsen with menstruation — and are among the most dramatically under-recognised endometriosis presentations in neurology and pain medicine.
Endometriosis and Central Sensitisation
A critically important and under-recognised dimension of endometriosis pain is central sensitisation — the neuroplastic upregulation of the spinal cord and brain's pain processing circuits that occurs in response to prolonged peripheral nociceptive input from endometriotic lesions. In central sensitisation, the dorsal horn neurons of the spinal cord become hyperexcitable through N-methyl-D-aspartate (NMDA) receptor-mediated mechanisms, wind-up phenomena, and descending inhibitory pathway failure — producing allodynia (pain from normally non-painful stimuli), hyperalgesia (exaggerated pain from normally painful stimuli), and pain that persists independent of peripheral input. Central sensitisation is documented in a significant proportion of women with endometriosis — particularly those with the longest diagnostic delays — and explains why complete surgical excision of all visible endometriotic disease, while necessary, is not always sufficient to eliminate pain. The patient whose pain persists after apparently successful complete excision is not a surgical failure, is not fabricating, and is not exhibiting disproportionate psychological response; she has a nervous system that has been sensitised by years of unaddressed peripheral inflammation and that requires a multimodal rehabilitation approach targeting central pain mechanisms in addition to, not instead of, management of any residual or recurrent endometriotic disease. Recognition of central sensitisation in endometriosis is one of the most important conceptual advances in understanding the condition's pain biology, and its therapeutic implications — including the role of neuromodulators, pain psychology, and pelvic physiotherapy — are increasingly incorporated into specialist endometriosis centre management pathways.
What Endometriosis Feels Like — The Full Clinical Spectrum
The clinical presentation of endometriosis is broader than most clinicians outside specialist centres appreciate. The cardinal symptom — severe cyclical pelvic pain — is the most commonly described and the most commonly dismissed. But endometriosis produces a range of symptoms that span pelvic anatomy, gastrointestinal function, urinary function, sexual function, fertility, and systemic wellbeing, and that collectively constitute a recognisable clinical profile that should, in any patient presenting with two or more of these symptoms together, trigger consideration of endometriosis as a primary diagnosis rather than the last one reached after years of symptom-by-symptom management.
"I started missing school at thirteen. By fifteen I was vomiting from the pain. By twenty, I had been told by four different doctors that period pain is normal and that I needed to learn to manage stress better. I was twenty-four when a junior doctor in an emergency department, seeing me in agony for the sixth time in a year, said: 'Has anyone ever tested you for endometriosis?' The laparoscopy found Stage III disease. The lesions on my uterosacral ligaments were so deep and fibrotic that the surgeon said the inflammatory damage must have been progressing for years. Eleven years. I lost eleven years to a condition that has a name, a biology, and a treatment — and all anyone had to do was look."
Oestrogen, Progesterone, and the Endometriotic Lesion — Why Hormones Drive Everything
Endometriosis is an oestrogen-dependent disease: endometriotic lesions express oestrogen receptors (ERα and ERβ) in proportions different from normal endometrium, with ERβ predominating over ERα (the reverse of the normal endometrium), and they synthesise oestrogen locally through the upregulation of aromatase (CYP19A1) — an enzyme that converts androgens to oestrogen within the lesion itself. This local oestrogen synthesis means that endometriotic lesions create their own oestrogenic environment independently of systemic oestrogen levels, which is one of the reasons why hormonal treatments that reduce systemic oestrogen do not reliably eliminate lesion activity completely and why recurrence occurs even after surgical excision in an oestrogen-reduced hormonal environment.
The relationship with progesterone is equally important and frequently more clinically consequential. Normal endometrium is progesterone-responsive: in the secretory phase, progesterone suppresses endometrial proliferation and promotes decidualisation. Endometriotic lesions demonstrate progesterone resistance — a documented relative inability to respond to progesterone through reduced progesterone receptor (PR-B) expression, altered downstream signalling, and epigenetic modifications that impair progesterone responsiveness. Progesterone resistance is the molecular reason why the combined oral contraceptive pill — which provides both oestrogen suppression and progestin exposure — is less effective in endometriosis than progestin-dominant regimens, and why high-dose progestins and progestin-only treatments (dienogest, norethindrone acetate, medroxyprogesterone acetate, the levonorgestrel IUS) are first-line hormonal treatments: they provide unopposed progestogenic stimulus that partially overcomes the lesion's relative resistance while suppressing ovarian oestrogen production, reducing the systemic oestrogenic drive to lesion growth.
The cyclical inflammatory activation of endometriotic lesions — producing prostaglandin E2, prostaglandin F2-alpha, and the cascade of cytokines and growth factors described above — is driven by and drives oestrogen synthesis in a positive feedback loop: oestrogen upregulates prostaglandin synthesis, prostaglandins upregulate aromatase, aromatase produces more local oestrogen. This autocrine loop sustains lesion activity independently of the systemic hormonal environment and is one of the mechanistic targets of aromatase inhibitors (letrozole, anastrozole) as a medical treatment for severe, refractory endometriosis.
Diagnosing Endometriosis — From Clinical Suspicion to Surgical Confirmation
Endometriosis diagnosis has historically required laparoscopy with histological confirmation of excised tissue — a standard that remains correct for definitive diagnosis but that has evolved with improvements in imaging to permit presumptive diagnosis and treatment initiation before surgery in patients with a characteristic clinical and imaging profile. The historical insistence on diagnostic laparoscopy before any treatment was initiated was a barrier to early management; current guidelines from the European Society of Human Reproduction and Embryology (ESHRE) and the Royal College of Obstetricians and Gynaecologists (RCOG) support empirical medical treatment in women with a clinically characteristic presentation of endometriosis without waiting for surgical confirmation, particularly where the primary symptom is pain rather than infertility. This is an important shift: it means that the clinician who identifies a probable endometriosis presentation in a young woman with dysmenorrhoea and deep dyspareunia is not obliged to wait for a laparoscopy list before commencing treatment — but it does not replace the diagnostic obligation in women who do not respond to empirical treatment, in whom malignancy must be excluded, or in whom surgical staging and excision are required for fertility or for bowel/urinary symptoms.
Clinical diagnosis — what to ask and what to examine
The clinical diagnosis of endometriosis begins with a detailed menstrual and pain history. The clinician must specifically ask — because patients frequently do not volunteer information they have been told is normal — about the severity of dysmenorrhoea on a numerical scale, its impact on daily function, the use of prescription analgesia, school or work absences related to menstruation, the presence of pain before menstrual flow onset, deep dyspareunia, dyschezia, cyclical bowel or bladder symptoms, and shoulder tip pain. A family history of endometriosis is significant — the relative risk of endometriosis is approximately six to eight times higher in first-degree relatives of affected women, reflecting strong genetic heritability. Physical examination should include abdominal palpation for uterine tenderness, bimanual pelvic examination for uterine retroversion (the retroverted, fixed uterus is a classic finding of posterior compartment endometriosis), uterosacral ligament nodularity, rectovaginal nodule palpation in the posterior fornix, and cervical excitation. These findings are pathognomonic when present but absent in superficial peritoneal disease and in patients examined outside the perimenstrual window — when lesion swelling and inflammatory activity are at their cyclical peak.
| Investigation | Role, Sensitivity, and Limitations | Clinical Application |
|---|---|---|
| Transvaginal Ultrasound (tvUS) | The first-line imaging investigation for suspected endometriosis. Highly sensitive and specific for ovarian endometriomas (sensitivity ~93%, specificity ~97% for endometriomas >1cm in experienced hands) using standardised IOTA (International Ovarian Tumour Analysis) criteria: homogeneous low-level "ground glass" echogenicity, absence of papillary projections with blood flow, typically unilocular. Also useful for detection of bladder endometriosis and — in the hands of an operator with specific training in deep endometriosis ultrasound — for posterior compartment mapping of rectosigmoid, uterosacral ligament, and rectovaginal nodules. Critical limitation: superficial peritoneal lesions are invisible on ultrasound. A normal tvUS does not exclude endometriosis. A normal tvUS in a patient with characteristic symptoms requires specialist review, not reassurance. The quality of ultrasound for endometriosis mapping is entirely operator-dependent; standard gynaecological ultrasound training does not include DIE mapping techniques. | First investigation in any woman with suspected endometriosis. Must be performed transvaginally (transabdominal ultrasound has significantly lower sensitivity for pelvic endometriosis). Ideally performed by a sonographer or clinician with specific endometriosis ultrasound training using the IDEA (International Deep Endometriosis Analysis) consensus protocol for systematic posterior compartment mapping. Results should be interpreted in clinical context: a normal scan does not exclude endometriosis. |
| MRI Pelvis (with bowel preparation) | The optimal imaging modality for complete endometriosis mapping prior to surgical planning, particularly for deep infiltrating endometriosis. MRI with bowel preparation (rectal enema, antiperistaltic agents) provides multiplanar soft tissue characterisation of: rectovaginal nodules (T2-hypointense fibromuscular nodules), bowel wall infiltration depth, ureteric involvement, bladder nodules, parametrial infiltration, and adenomyosis (junctional zone characteristics). Sensitivity for bowel DIE: approximately 83–90% for experienced radiologists reading endometriosis-protocol MRI. A standard gynaecological MRI read by a radiologist without specific endometriosis training will miss the majority of DIE findings. MRI cannot reliably detect superficial peritoneal lesions or small vesicular lesions. Diagnostic accuracy for MRI in endometriosis is critically dependent on the radiologist's specific expertise and the imaging protocol used. | Indicated when: tvUS identifies endometrioma and DIE is suspected; symptoms suggest posterior compartment or bowel involvement; pre-surgical mapping for complex disease; ureteric involvement needs exclusion; clinical suspicion of DIE with normal or non-specialist ultrasound. Should be reported by a radiologist with specific endometriosis MRI training, using a dedicated endometriosis MRI protocol including T1 fat-saturated, T2 in three planes, and bowel preparation. Essential before complex DIE surgery. |
| CA-125 (serum cancer antigen 125) | CA-125 is a glycoprotein shed by peritoneal mesothelial cells and by endometriotic lesions under inflammatory stimulation. It is elevated (above 35 IU/mL, the conventional upper limit of normal) in approximately 20–50% of women with endometriosis — the sensitivity is too low for it to function as a screening test. It is more commonly elevated in Stage III–IV than Stage I–II disease. Crucially, CA-125 is elevated in multiple other conditions — ovarian malignancy, fibroids, adenomyosis, pelvic inflammatory disease, endometrial cancer — making a positive result non-specific. Its principal clinical use in endometriosis is: serial monitoring of known disease burden in treated patients; supporting a clinical diagnosis of endometriosis in a patient with characteristic symptoms and elevated CA-125; and as a component of risk stratification panels (alongside ultrasound features) to help distinguish endometrioma from potential ovarian malignancy before surgery. | Not recommended as a screening test for endometriosis. May be helpful as a supportive biomarker in women with characteristic endometriosis symptoms and elevated levels, providing additional evidence to support specialist referral. Serial measurement may provide useful monitoring information in patients with known, treated endometriosis. Always interpret in conjunction with clinical findings and imaging, not as a standalone diagnostic. |
| Diagnostic Laparoscopy with Histology | The gold standard for definitive endometriosis diagnosis: direct visualisation of endometriotic lesions with biopsy and histological confirmation of endometrial glands and/or stroma in excised tissue. Laparoscopy allows complete anatomical mapping and simultaneous surgical treatment (excision of all visible disease at the same procedure). Critical principle: a diagnostic laparoscopy should always be a therapeutic laparoscopy — every endometriotic lesion that can be safely excised should be excised at the diagnostic procedure, not left in situ for a separate operating list. Multiple morphological appearances must be specifically sought including clear, red, and white atypical lesions that are routinely missed by surgeons without specific endometriosis training. The sensitivity of diagnostic laparoscopy is critically dependent on the surgeon's expertise: population studies document significant lesion under-recognition rates in general gynaecology operating lists compared to specialist endometriosis centres. | Indicated when: empirical medical management fails to control symptoms adequately; infertility investigations require pelvic assessment; imaging identifies features requiring surgical management (endometrioma, suspected DIE); malignancy cannot be excluded on imaging; patient requires surgical confirmation before long-term hormonal management. Should ideally be performed by or in consultation with a surgeon with specific endometriosis surgical training. Histological confirmation of all excised tissue is mandatory — visual diagnosis alone may miss histological disease in atypical lesions, and macroscopic appearance does not exclude malignancy in complex ovarian lesions. |
| Biomarkers Under Investigation | The search for a non-invasive biomarker for endometriosis diagnosis — enabling early identification without laparoscopy — is one of the most active research areas in the field. Candidates include: serum microRNA panels (miR-200b, miR-145, and others show differential expression); endometrial biomarkers (nerve fibre density in endometrial biopsy, expression of NF-kB, thrombospondin-1); urine biomarkers (CXCL-8, VEGF); peripheral blood cell-free DNA methylation patterns; and menstrual effluent analysis. None has yet reached clinical diagnostic accuracy sufficient for routine use, but this field is rapidly advancing. The Endometriosis Foundation of America (EndoFound) and several international research consortia are funding large-scale biomarker validation studies with the specific aim of developing a blood or urine test capable of identifying endometriosis in primary care — a development that would fundamentally alter the diagnostic timeline. | Currently investigational only — not in routine clinical use. Patients and clinicians should be aware of this active research space. Participation in biomarker research studies where available may benefit both individual patients (access to closer monitoring) and the broader patient population (accelerating development of non-invasive diagnostics). Endometriosis UK and EndoFound maintain listings of current research studies open to participant recruitment. |
What Endometriosis Gets Called Instead — Years in the Wrong Consultation Room
The misdiagnosis landscape of endometriosis is as consistent and as damaging as any in medicine. Because the symptoms span multiple organ systems and because the disease's defining symptom — pelvic pain — is normalised in women by culture and by medical culture simultaneously, the patient with endometriosis navigates a diagnostic journey that passes through multiple specialty waiting rooms, each of which addresses the symptom relevant to that specialty without recognising the endometriotic mechanism that underlies them all.
Irritable Bowel Syndrome (IBS): The most common misdiagnosis in endometriosis, particularly when bowel symptoms predominate. Women with bowel endometriosis spend an average of five years in gastroenterology clinics before the pelvic origin of their symptoms is identified. The cyclical pattern of bowel symptoms — worse with menstruation — is the critical distinguishing feature that should be specifically asked about in every woman diagnosed with IBS of reproductive age. Primary Dysmenorrhoea: The single most pervasive and most harmful misattribution: the assumption that severe period pain is primary dysmenorrhoea — physiological pain without structural cause — rather than secondary dysmenorrhoea caused by endometriosis. The distinction that matters clinically: primary dysmenorrhoea improves with age and after pregnancy; endometriosis pain is progressive and does not reliably improve with pregnancy, and often worsens. Interstitial Cystitis / Bladder Pain Syndrome: Bladder endometriosis and uterosacral ligament DIE produce symptoms indistinguishable from IC/BPS. All women of reproductive age with IC/BPS symptoms should be evaluated for endometriosis before the IC/BPS diagnosis is finalised. Pelvic Inflammatory Disease (PID): Acute-on-chronic pelvic pain in endometriosis — particularly during menstruation — is treated as acute PID and managed with antibiotics, without microbiological confirmation and without investigation of the underlying structural cause. Repeated PID diagnoses without positive cultures are a red flag for endometriosis. Ovarian Cyst: Endometriomas are repeatedly aspirated rather than excised, drained laparoscopically without cyst wall removal, or managed expectantly with the wrong description of "functional cyst" — all approaches that produce recurrence and continued ovarian damage. Anxiety and Somatoform Disorder: The patient who returns repeatedly with pelvic pain, whose investigations are normal (because peritoneal disease is not imaged by standard pelvic ultrasound), and who is visibly distressed by unmanaged pain is categorised as having disproportionate symptom reporting. This is the most harmful diagnostic conclusion in endometriosis, because it closes the clinical pathway that might otherwise lead to laparoscopy. Vulvodynia / Vaginismus: Deep dyspareunia from uterosacral or posterior vaginal fornix endometriosis is attributed to pelvic floor hypertonicity or vulvar pain disorders without investigation of the posterior compartment for structural endometriotic pathology. Pelvic physiotherapy may help the secondary pelvic floor dysfunction but will not treat the endometriosis producing it. Depression: The depressive symptoms of endometriosis — themselves partly biologically driven by systemic inflammation — are treated pharmacologically without addressing the endometriotic disease generating both the inflammation and the social, functional, and reproductive losses that compound the biological depressive burden.
Treating Endometriosis — The Surgical, Hormonal, and Multimodal Framework
Endometriosis treatment is stratified by symptom profile, disease distribution, fertility goals, disease severity, and patient preference, and it operates across three complementary domains: surgical excision of endometriotic tissue (addressing the source of inflammation and structural disruption), hormonal medical management (suppressing the oestrogenic drive to lesion growth and activity), and multimodal pain management (addressing central sensitisation, pelvic floor dysfunction, and the systemic consequences of chronic pain). These domains are not mutually exclusive and the best outcomes in severe disease require combining all three.
Surgical treatment — the case for excision over ablation
The surgical management of endometriosis has undergone significant evolution in the understanding that the technique of surgical intervention — excision versus ablation — and the completeness of removal are the primary determinants of surgical outcome and recurrence rate. Ablation techniques (laser vaporisation, electrocautery diathermy of lesion surfaces) destroy the visible surface of endometriotic lesions without removing the underlying tissue, leaving viable endometriotic glands and stroma beneath the carbonised surface — a mechanism of disease that explains both incomplete symptom resolution and the high recurrence rates (up to 40–50% at five years) after ablative surgery. Excision — the complete surgical removal of endometriotic lesions including their margins and underlying involved tissue — removes the entire lesion and its peritoneal base, producing superior pain outcomes at five years compared to ablation in randomised controlled trials, and is the surgical standard recommended by specialist endometriosis societies including the BSGE (British Society for Gynaecological Endoscopy) and the AAGL (American Association of Gynecologic Laparoscopists).
| Surgical Procedure | Indication and Description | Evidence and Considerations |
|---|---|---|
| Peritoneal Excision (Laparoscopic) | Complete laparoscopic excision of all visible peritoneal endometriotic lesions, including their peritoneal base and lateral margins, using cold scissors, monopolar or bipolar electrosurgery, CO2 laser, or ultrasonic energy devices. All morphological subtypes of lesion must be specifically identified and excised — including atypical clear and red lesions that may not produce the classic "powder burn" appearance. The raw peritoneal surface after excision is typically left to heal by secondary intention; extensive raw areas may be covered with adhesion prevention barriers. | The standard of care for symptomatic superficial peritoneal endometriosis at specialist centres. A landmark randomised controlled trial by Abbott and colleagues (2004) demonstrated significant improvement in pain and quality of life after laparoscopic excision compared to diagnostic laparoscopy alone. Recurrence rates after complete excision are significantly lower than after ablation. Requires a surgeon trained in recognising all morphological subtypes of peritoneal endometriosis — the missed lesion cannot be excised. Should be performed at a centre with adequate surgical volume to maintain skill. |
| Ovarian Cystectomy (Endometrioma) | Laparoscopic excision of the endometrioma cyst wall by the "stripping technique" (mobilising the cyst wall at the natural cleavage plane between cyst capsule and normal ovarian cortex, using a combination of sharp dissection and traction-countertraction to peel the cyst lining away from the ovary) followed by haemostasis with bipolar diathermy applied sparingly to preserve adjacent follicle-bearing cortex. Drainage and irrigation of the cyst contents alone (aspirate-only approach) is not adequate treatment for endometriomas: it does not remove the endometriotic cyst lining, recurrence is essentially universal, and drainage without excision restores the damage of another endometrioma cycle. | Stripping cystectomy versus ablation of the cyst lining: a Cochrane review (Hart et al.) demonstrated that stripping cystectomy produces significantly lower recurrence rates, significantly better spontaneous pregnancy rates, and better-preserved ovarian reserve (as measured by follicle counts) compared to ablation of the cyst interior. Critical surgical principle: haemostasis after stripping must use the minimum effective energy — excessive bipolar application to the ovarian base destroys normal follicle-bearing cortex. Ovarian reserve testing (AMH, AFC) before and after endometrioma surgery is recommended to document any impact. In women with bilateral endometriomas or prior ovarian surgery, fertility preservation counselling is essential before operating, including discussion of oocyte cryopreservation. |
| Deep Infiltrating Endometriosis (DIE) Excision | The most surgically complex endometriosis procedure: complete excision of deep endometriotic nodules from the uterosacral ligaments, rectovaginal septum, bowel wall, bladder, vaginal fornix, and parametria. Requires advanced laparoscopic surgical skills and — for bowel and ureteric involvement — a multidisciplinary approach with colorectal and/or urological surgical input. Bowel DIE may require: shaving of the bowel muscularis (removal of superficial bowel muscle invasion without entering the bowel lumen, preserving luminal continuity); disc excision (full-thickness excision of a disc of bowel wall with primary closure, appropriate for lesions involving less than 30–40% of the bowel circumference and less than 3cm); segmental bowel resection with anastomosis (complete removal of the affected bowel segment with end-to-end reconnection, appropriate for larger, longer, or more circumferential lesions, or where multiple disc excisions would be required within a short bowel segment) — which carries risks of anastomotic leak (1–3%), rectovaginal fistula, bladder dysfunction, and altered bowel habit that must be disclosed in detail. | Should only be performed at BSGE-accredited or equivalent specialist endometriosis centres, by surgeons with documented training and surgical volume in DIE surgery. Outcomes data from specialist centres demonstrate significantly better pain outcomes, lower complication rates, and lower recurrence rates than non-specialist surgery. Pre-operative bowel preparation, ureteric stenting in cases with ureteric proximity, and intraoperative colorectal consultation are standard components of complex DIE operating protocols. Post-operative complications including bowel dysfunction, bladder atony (requiring temporary urinary catheterisation), and de novo nerve injury must be discussed pre-operatively. The "Ferrari surgeon" principle applies: the complexity of the surgery requires the surgeon to have performed it many times to do it well. |
| Hysterectomy ± Bilateral Salpingo-oophorectomy (BSO) | Hysterectomy — removal of the uterus — is considered in women with endometriosis who have completed their families, who have failed multiple conservative surgical and medical treatments, who have co-existing adenomyosis significantly contributing to pain and bleeding, or who specifically request this approach. Hysterectomy alone (without oophorectomy) is not a curative procedure for endometriosis: it does not remove extrauterine endometriotic lesions, and these lesions continue to be stimulated by the remaining ovarian oestrogen. Bilateral salpingo-oophorectomy (BSO) in addition to hysterectomy removes the primary ovarian oestrogen source, producing a significant reduction in disease activity — but at the cost of surgical menopause in premenopausal women, with all its attendant risks including bone density loss, cardiovascular effects, sexual dysfunction, and cognitive changes. BSO in women under 45 is associated with increased all-cause mortality in the long term; hormone replacement therapy (HRT) substantially mitigates this risk but requires careful prescribing consideration in women with endometriosis (continuous combined or progestin-dominant regimens preferred over cyclical regimens to minimise endometrial stimulation). | Should be considered the final surgical option after conservative surgical and medical management has been optimised, not an early or routine treatment. It is not appropriate to perform hysterectomy for endometriosis in a woman who wishes to preserve fertility or who has not had the opportunity to access specialist endometriosis excision surgery. The decision to perform BSO at the time of hysterectomy requires individualized counselling about the specific benefits (disease control) and risks (surgical menopause) for each patient's age, fertility status, disease burden, and symptom profile. Post-hysterectomy endometriosis, including in the vaginal vault and in previously unexcised peritoneal sites, occurs in approximately 10–15% of cases where disease excision was incomplete at the time of hysterectomy. |
Hormonal medical management — the treatment pyramid
Hormonal medical management of endometriosis operates by two primary mechanisms: suppression of ovarian oestrogen production (reducing the systemic hormonal drive to lesion growth and activity) and direct anti-proliferative and anti-inflammatory effects on endometriotic lesion tissue (through progestins, which partially overcome the lesion's progesterone resistance). These mechanisms are complementary rather than redundant, which is why the most effective medical treatments in clinical practice typically combine both. No currently available hormonal treatment eliminates endometriosis — it suppresses active disease during the treatment period, with disease activity recurring in a proportion of patients on cessation of treatment. This is not a treatment failure; it is the expected biology of a disease that requires ongoing management over a reproductive lifetime.
| Treatment | Mechanism and Agents | Efficacy, Adverse Effects, and Clinical Notes |
|---|---|---|
| Progestins (first-line hormonal) | Dienogest (2mg daily) — the most endometriosis-specific oral progestin, with strong anti-proliferative effects on endometriotic tissue via PR-mediated pathways and significant local anti-angiogenic and anti-inflammatory activity. Norethindrone acetate (NETA, 5–10mg daily). Medroxyprogesterone acetate (MPA, 30–50mg daily or as Depo-Provera injection). Dydrogesterone (10–20mg daily, days 5–25 or continuously). | Dienogest has the strongest clinical trial evidence base specifically in endometriosis, with randomised controlled trials demonstrating significant pain reduction equivalent to GnRH agonist treatment with a more favourable bone density safety profile and without the need for add-back HRT. Levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena 52mg): highly effective local progestin delivery directly to the uterus — particularly effective for dysmenorrhoea and adenomyosis-associated heavy menstrual bleeding; produces very low systemic progestin levels. Progestin side effects: irregular breakthrough bleeding (particularly in the first three months), mood changes (depression and anxiety, particularly with high-dose progestins — must be monitored and should not be attributed to the endometriosis alone), weight gain (modest, variable), acne, and — at high doses — adverse lipid profile changes. Breakthrough bleeding is the most common reason for early discontinuation and can often be managed by brief addition of oestrogen or by waiting for a three-month adaptation period. |
| Combined Oral Contraceptive Pill (OCP) | Low-dose combined oestrogen-progestin pills used continuously (no pill-free interval) or with extended cycles — suppressing menstruation and the cyclical inflammatory activation of lesions. Continuous use produces amenorrhoea in a proportion of women, reducing or eliminating the cyclical pain episodes associated with menstruation. | Effective for pain management in many women with endometriosis, particularly superficial peritoneal disease and adenomyosis-associated dysmenorrhoea. Less effective than progestin-dominant regimens or GnRH analogues for severe deep infiltrating disease. The pill-free interval — even in a standard 21-day/7-day cycle — permits a hormonal withdrawal bleed with associated inflammatory activation; continuous or extended cycling that eliminates this interval improves symptom control. Not appropriate as a long-term solution in women with DIE where progestin-dominant suppression or surgical management is required. Contraindicated in women with migraine with aura (increased stroke risk), high thrombotic risk, and certain other medical conditions. |
| GnRH Agonists (with add-back HRT) | Gonadotropin-releasing hormone agonists (leuprorelin/leuprolide, nafarelin, buserelin, goserelin) produce initial transient gonadotropin stimulation (the "flare" effect) followed by pituitary GnRH receptor downregulation and suppression of FSH and LH, reducing ovarian oestrogen production to post-menopausal levels. This profound oestrogen suppression produces lesion quiescence but also causes the full menopausal symptom burden — hot flushes, night sweats, vaginal atrophy, bone density loss, and cognitive effects. Add-back HRT (oestrogen ± progestin, at low doses sufficient to control menopausal symptoms without reactivating endometriosis) is mandatory with GnRH agonist treatment beyond three months and substantially mitigates bone density loss and menopausal symptoms without significantly compromising endometriosis control. | Highly effective for pain control in endometriosis, including severe DIE — pain reduction rates of 85–90% during treatment. Used primarily when other medical management has failed, as a pre-operative down-staging treatment for complex DIE, or as post-operative maintenance to delay recurrence after surgical excision. Standard treatment duration with add-back is up to two years. Bone density loss remains a concern even with add-back — regular DEXA scanning is recommended for women on GnRH agonists for more than six months. Do not use without add-back HRT beyond three months under any circumstances — the bone density loss of six months' unopposed GnRH agonism is clinically significant and may not fully recover. |
| GnRH Antagonists (newer agents) | GnRH antagonists (elagolix/Orilissa, relugolix, linzagolix) block GnRH receptors directly without the initial agonist flare, producing rapid, dose-dependent oestrogen suppression that is both faster in onset and — critically — reversible: FSH/LH and oestrogen levels recover rapidly on cessation. Oral formulations (unlike the injectable GnRH agonists) provide the additional advantage of daily dosing adjustment. Elagolix is approved for endometriosis pain management in the USA; relugolix combined tablet (relugolix + oestradiol + norethindrone acetate, Ryeqsa/Oriahnn) is approved for endometriosis-associated pain management with built-in hormonal add-back in a single tablet formulation. | GnRH antagonists offer several clinical advantages over agonists: no initial flare, no injection required (oral dosing), rapid reversibility, and dose-titratable oestrogen suppression (lower doses preserve some ovarian oestrogen while still suppressing endometriosis activity, enabling a "partial suppression" approach that may better balance efficacy against hypoestrogenic side effects). The combined relugolix tablet (with built-in add-back) provides a single-pill management option that simplifies the GnRH agonist + add-back two-prescription approach. These agents represent the most significant advance in endometriosis medical management in two decades and are expected to become an important component of first-line specialist management as prescribing access expands. |
| Aromatase Inhibitors | Letrozole (2.5mg daily) or anastrozole (1mg daily) inhibit aromatase (CYP19A1) — the enzyme that converts androgens to oestrogen, upregulated in endometriotic lesions. This targets the local autocrine oestrogen production within lesion tissue that sustains activity independently of systemic ovarian oestrogen. Must be combined with ovarian suppression (progestin, OCP, or GnRH agonist) to prevent compensatory ovarian oestrogen production in premenopausal women — aromatase inhibitor monotherapy stimulates ovarian follicular development through the feedback loop, partially defeating its own purpose. | Reserved for refractory endometriosis — women who have failed standard hormonal management and post-surgical recurrence. Clinical trial evidence (primarily from cohort studies and a small number of RCTs) demonstrates significant pain improvement in 75–80% of women with refractory disease. Most evidence is from the postmenopausal setting; in premenopausal women, concurrent ovarian suppression is essential. Bone density monitoring is required. Side effects include joint pains, hot flushes, headache, and hyperlipidaemia. Prescribing currently by specialist endometriosis clinicians only — not a primary care or general gynaecology prescription. |
| NSAIDs and Analgesic Management | Non-steroidal anti-inflammatory drugs (naproxen 500mg twice daily, mefenamic acid 500mg three times daily, ibuprofen 400–600mg three to four times daily) inhibit cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thereby reducing the prostaglandin-mediated component of endometriosis-associated pain. Celecoxib (COX-2 selective) may offer fewer GI side effects in women requiring long-term or frequent NSAID use. Starting NSAIDs one to two days before expected menstrual onset (pre-emptive dosing) is more effective than starting at pain onset. NSAIDs should be taken with food and used with caution in women with renal or GI comorbidities. | NSAIDs reduce but do not eliminate dysmenorrhoea in endometriosis — they address the prostaglandin component of pain but not the direct nerve stimulation from active lesions. They are appropriate as symptomatic adjuncts alongside hormonal and surgical management, not as the primary or sole treatment. Women requiring high-dose or frequent NSAIDs to function — and particularly women who do not get adequate relief from standard doses — need specialist evaluation, not escalating NSAID prescriptions as a substitute for diagnosis and definitive treatment. Opioid analgesics: opioids are not an appropriate long-term management strategy for endometriosis pain and should not replace specialist assessment and treatment — but adequate analgesia for severe episodes is a legitimate pain management need and should not be withheld on ideological grounds while the patient awaits specialist assessment. |
Endometriosis and Fertility — The Mechanisms, the Management, and the Timeline
The impact of endometriosis on fertility is one of its most clinically significant consequences and one of the most important arguments for early diagnosis and management. The mechanisms by which endometriosis impairs fertility are multiple, anatomically distributed, and cumulative — meaning that the longer the disease is active and the more advanced it becomes, the greater the fertility impairment. This is not a counsel of despair: even women with severe endometriosis can achieve pregnancy through a combination of surgical optimisation and — where necessary — assisted reproductive technology (ART). But the window in which fertility preservation is most effective is earlier rather than later, which is precisely the window that diagnostic delay closes.
In Stage I–II endometriosis (minimal-mild disease), the fertility impact is mediated predominantly by peritoneal inflammation — the altered peritoneal environment impairs sperm function, oocyte quality, tubal motility, and embryo development through the effects of elevated IL-6, IL-8, VEGF, and reactive oxygen species in the peritoneal fluid. Women with minimal-mild endometriosis and otherwise unexplained infertility benefit from laparoscopic excision of endometriotic lesions: a landmark Canadian randomised controlled trial by Marcoux and colleagues demonstrated a significantly higher cumulative pregnancy rate over 36 weeks after laparoscopic surgery compared to diagnostic laparoscopy alone (30.7% vs 17.7%), establishing excision as the appropriate treatment for infertility associated with early-stage disease before resorting to ART.
In Stage III–IV endometriosis, the picture is more complex. Endometriomas impair the ovarian reserve directly and must be carefully managed — complete cystectomy by the stripping technique, performed by an experienced surgeon minimising normal cortex removal and using conservative haemostasis, is the appropriate treatment before ART. Women with bilateral endometriomas or prior ovarian surgery are at high risk of significantly reduced ovarian reserve post-operatively and should be offered oocyte or embryo cryopreservation before surgery if they have not yet completed their families, to preserve the fertility they have before the surgery that risks reducing it further. In vitro fertilisation (IVF) outcomes in endometriosis: multiple meta-analyses demonstrate reduced ovarian response, reduced fertilisation rates, and reduced implantation and live birth rates per cycle in women with endometriosis compared to age-matched controls — but pregnancy is achievable, and cumulative live birth rates over multiple IVF cycles are meaningful. Pre-IVF treatment with GnRH agonist for three to six months (the "long protocol" downregulation) has demonstrated improved IVF outcomes in some studies, possibly by reducing the inflammatory peritoneal environment and improving endometrial receptivity.
Endometriosis is found in 25–50% of women investigated for infertility. Every year of diagnostic delay is a year of progressive ovarian reserve reduction, progressive adhesion formation, and progressive peritoneal inflammatory damage to the reproductive environment. The appropriate response to "we'll investigate infertility if you haven't conceived in 12 months" in a woman with symptoms of endometriosis is not 12 months of waiting. It is immediate investigation and specialist referral. The disease does not pause during the waiting period.
Endometriosis in the Context of the Series — The Multi-System Patient
Endometriosis does not exist in isolation for many of the patients most severely affected by it. The conditions described throughout this series — hypermobile Ehlers-Danlos Syndrome, mast cell activation syndrome, dysautonomia and POTS, complex nerve compression — co-occur with endometriosis at rates that are not coincidental and that reflect shared underlying biology rather than diagnostic overlap artifact.
The endometriosis-hEDS association is documented in specialist cohort data and reflects the shared connective tissue matrix biology: women with hypermobile connective tissue have altered extracellular matrix in the pelvic peritoneum and ligamentous structures, potentially increasing susceptibility to endometriotic implantation and altering the mechanical environment of lesion growth. Mast cell activation syndrome co-exists with endometriosis through multiple bidirectional mechanisms — endometriotic lesions directly activate peritoneal mast cells through prostaglandin and cytokine cross-stimulation, and mast cell mediators amplify the inflammatory environment of existing lesions and lower pain thresholds through the neurogenic mechanisms described in Article 6. Women with MCAS and endometriosis frequently have treatment challenges at the interface of the two conditions: hormonal treatments for endometriosis can trigger mast cell flares (oestrogen directly activates mast cells through membrane receptors), and mast cell medications may interact with endometriosis pain management. These interactions require specialist co-management, not independent parallel management by separate specialists who are unaware of the other condition.
Dysautonomia and POTS in endometriosis likely reflect shared neurogenic inflammation — the autonomic ganglia of the pelvis are anatomically proximate to endometriotic lesion sites, particularly in posterior compartment DIE, and chronic pelvic neurogenic inflammation may destabilise autonomic regulation. Pudendal nerve involvement, inferior hypogastric plexus invasion, and sciatic nerve perineural endometriosis can produce specific autonomic symptoms in addition to pain. The "invisible catastrophe" nature of severe endometriosis — multi-system, episodic, invisible on standard investigations, predominantly affecting young women, and consistently attributed to psychological causes — places it alongside every other condition in this series in the same diagnostic and cultural failure mode.
Beyond Surgery and Hormones — Multimodal Pain Management in Endometriosis
Surgical excision and hormonal suppression are the cornerstone treatments for endometriosis, but they are not the complete clinical picture for the majority of women with moderate-to-severe disease, whose pain experience is shaped not only by active lesion biology but by the secondary neuroplastic changes of central sensitisation, pelvic floor dysfunction, gut dysmotility, and the psychological burden of chronic illness. Comprehensive endometriosis care — as delivered at the best specialist centres — integrates the following components alongside surgery and hormonal management.
Pelvic Physiotherapy
Pelvic floor physiotherapy — delivered by a physiotherapist with specialist training in pelvic floor assessment and rehabilitation — addresses the secondary pelvic floor hypertonicity that develops in virtually all women with chronic pelvic pain from any cause, including endometriosis. The pelvic floor's protective guarding response to chronic pain produces a cycle of muscle hypertonicity, increased pelvic floor pressure, nerve compression, and pain that compounds and perpetuates the primary endometriosis pain in the absence of treatment. Pelvic physiotherapy techniques include internal myofascial release, external trigger point therapy, neural mobilisation of pudendal and sciatic nerve pathways, and progressive pelvic floor relaxation and coordination exercises. It is not a substitute for surgical treatment — it does not treat the endometriotic lesions — but it is an essential component of pain rehabilitation, particularly post-operatively when residual pelvic floor dysfunction persists despite successful lesion excision. Equally, women awaiting surgery who have been on long waiting lists benefit from pelvic physiotherapy to maintain function and manage the secondary pelvic floor component of their pain in the interim. Every endometriosis specialist centre should have integrated pelvic physiotherapy.
Neuromodulators for Central Pain
When central sensitisation is a significant contributor to persistent pain — identified by the clinical features of allodynia, hyperalgesia, widespread (non-anatomical) pain distribution, and pain that persists despite apparently complete surgical excision — neuromodulatory medications targeting central pain processing pathways are clinically appropriate. Amitriptyline (10–75mg nightly) is the most widely used first-line neuromodulator for central sensitisation in endometriosis: it acts on serotonin and noradrenaline reuptake, sodium channels, and NMDA receptors to reduce central pain sensitivity, and at low antidepressant doses has a beneficial side effect profile (improved sleep quality, which is independently important in pain modulation) relative to its risk. Duloxetine (30–60mg daily) — a serotonin-noradrenaline reuptake inhibitor — has evidence in other central sensitisation conditions and is increasingly used in refractory endometriosis pain. Gabapentinoids (gabapentin, pregabalin) target voltage-gated calcium channels involved in dorsal horn sensitisation and are appropriate for neuropathic components of endometriosis pain, including sciatic or pudendal nerve involvement, but should be used with caution in women of childbearing age given teratogenic potential concerns. Low-dose naltrexone (LDN, 1.5–4.5mg nightly) has emerging evidence in central sensitisation and in mast cell-mediated inflammatory conditions co-occurring with endometriosis.
Pain Psychology and CBT
Pain-focused psychological intervention in endometriosis is not — and this distinction is critical — an alternative to surgical and medical treatment, and it must never be offered as a substitute for investigation and physical management. It is an evidence-based adjunct to physical treatment that addresses the modifiable psychological components of the chronic pain experience: pain catastrophising (the tendency to ruminate on pain, feel helpless in relation to it, and expect the worst — which amplifies pain intensity through corticolimbic pain amplification pathways), pain-related fear and avoidance behaviours that restrict function beyond what the underlying disease requires, the grief and loss associated with fertility impact and life limitation, and the depression and anxiety that compound the biological neuropsychiatric burden of the disease. Cognitive Behavioural Therapy for chronic pain (pain-CBT), Acceptance and Commitment Therapy (ACT), and pain-focused mindfulness-based stress reduction (MBSR) all have evidence for meaningful improvement in pain-related disability, quality of life, mood, and daily function in endometriosis — not by reducing the pain per se (the lesions remain), but by improving the relationship with pain and reducing the secondary suffering it generates. Pain psychology should be introduced alongside physical management, not as a final resort when all physical management has been exhausted or dismissed.
Diet, Inflammation, and Self-Management
The relationship between diet, systemic inflammation, and endometriosis is an area of active research with emerging but not yet definitive clinical evidence. What is reasonably supported by the current literature: a diet rich in omega-3 fatty acids (oily fish, flaxseed, walnuts) reduces prostaglandin synthesis through competitive inhibition of arachidonic acid metabolism and has demonstrated modest reductions in dysmenorrhoea severity in controlled trials. A diet low in trans fats and refined carbohydrates reduces systemic inflammatory markers (C-reactive protein, IL-6) relevant to endometriosis. Adequate vitamin D status is associated with reduced endometriosis severity in some epidemiological studies, and vitamin D deficiency — highly prevalent in Northern European populations — is worth correcting. Anti-inflammatory dietary patterns (Mediterranean diet) are appropriate to recommend as part of comprehensive endometriosis management, with the explicit caveat that they are adjunctive — they do not replace surgical or hormonal treatment, and eliminating entire food categories without evidence of personal sensitivity is likely to cause nutritional harm. Heat therapy for menstrual pain (heating pad, hot water bottle, TENS units) provides modest but real analgesia and should be recommended as a self-management tool alongside medication. Regular moderate exercise — adapted to capacity on symptomatic days — has analgesic and anti-inflammatory effects and should be encouraged alongside appropriate rest during severe episodes.
Accredited Specialist Endometriosis Centres
The most important structural intervention in endometriosis management is referral to an accredited specialist endometriosis centre — a clinical unit with designated endometriosis multidisciplinary team (MDT) meetings, a specialist endometriosis surgeon with documented training and surgical volume, integrated pelvic physiotherapy, pain psychology, specialist endometriosis nursing support, and colorectal/urological surgical collaboration for complex DIE. In the UK, BSGE (British Society for Gynaecological Endoscopy) accredits specialist and complex endometriosis centres against defined criteria. In the USA, the Endometriosis Foundation of America (EndoFound) and the American Board of Minimally Invasive Gynecologic Surgery (ABMIG) accredit centres. In Australia, the Endometriosis Australia national clinical network provides a referral directory. The outcomes difference between specialist centre care and general gynaecology management for endometriosis is substantial and documented — surgical recurrence rates, complication rates, symptom resolution, and quality of life outcomes are significantly better after specialist centre surgery than after non-specialist surgery. Every woman with suspected or confirmed endometriosis, particularly those with bowel symptoms, posterior compartment pain, prior failed surgery, or suspected deep infiltrating disease, should be referred to or managed in consultation with a specialist endometriosis centre.
Patient Organisations and Self-Advocacy
The patient organisations working in endometriosis have been instrumental in driving diagnostic awareness campaigns, funding research, improving clinical guidelines, and providing the information support that the medical system often fails to offer. Endometriosis UK (endometriosis-uk.org) provides a BSGE specialist centre directory, patient information leaflets, a helpline, and a patient support network. Endometriosis Australia (endometriosisaustralia.org) provides similar national resources. The Endometriosis Foundation of America (EndoFound, endofound.org) funds research and provides a US specialist directory. World Endometriosis Society (endometriosis.ca) maintains international clinical guidelines and a global clinician network. Nancy's Nook Endometriosis Education — a private Facebook group founded by Nancy Peterson, a nurse specialist — provides a curated, evidence-based educational resource for patients and clinicians and maintains a community-built international directory of excision surgeons based on surgical philosophy and approach, used by millions of patients globally when seeking a specialist. Patients navigating the endometriosis diagnostic and treatment journey are advised to: document all symptoms with dates and severity ratings; track cyclical patterns explicitly; prepare for consultations with written symptom summaries; ask specifically whether posterior compartment assessment has been performed; ask whether any proposed surgery will include histological biopsy and confirmation; and ask for referral to a specialist centre if general gynaecology management has not achieved adequate symptom control.
The Gender Dimension — Medicine's Most Consistent Failure
The diagnostic delay in endometriosis is inseparable from the gender of the population it affects. Endometriosis is a disease of women — of their biology, of the specific tissue that constitutes their reproductive function — and it is a disease whose defining symptom has been, for the entirety of medicine's history, categorised as normal. Dysmenorrhoea — pain with menstruation — has been so thoroughly incorporated into the cultural and medical concept of female experience that its pathological forms have been systematically invisible, not because they are subtle but because they have been embedded in a category that does not admit pathology. "Period pain" is expected. Its severity is expected to be variable. Its disruption of normal function is accepted as part of being female. The medical consequence of this cultural construction is the structure of the diagnostic delay: every clinician in the diagnostic pathway who tells a girl or woman with endometriosis that her pain is normal is not expressing a clinical opinion based on examined evidence. They are expressing a cultural expectation about what female pain means — and they are expressing it without examination, without measurement, and without investigation.
The pain of endometriosis is not disproportionate to the disease. Studies using validated pain instruments and quality-of-life measures consistently document pain scores in endometriosis that are equivalent to or exceed those of conditions in male-predominant populations that receive urgent investigation and aggressive management — including renal colic, acute cardiac pain, and cluster headache. The woman who describes pain that keeps her in bed, that requires her to vomit into a bin by her desk while continuing to work because she cannot afford another sick day attributable to "cramps," who takes the maximum dose of three different analgesics and gets no adequate relief, is not experiencing pain within the tolerable normal range. She is experiencing a medical emergency that has been constructed as ordinary.
Pain that prevents you from attending school, from going to work, from eating or walking on the days when it is worst — pain that has been doing this, reliably, every month, since you were thirteen — is not normal menstruation. It is a medical symptom. The correct clinical response to that symptom is investigation, not reassurance. The failure of investigation is not evidence of normality. It is evidence of a system that decided, before it looked, what the answer was.
Research investment in endometriosis is beginning to reflect the scale of the condition's burden, but the historical underfunding is stark. A 2020 analysis found that endometriosis research received approximately £16 of research funding per patient affected in the UK, compared to approximately £260 for asthma and £1,500 for diabetes — conditions of similar or lesser population prevalence in comparable demographic groups. The mechanisms by which research funding flows toward conditions with organised research infrastructure, advocacy, and — critically — male-predominant patient populations, at the expense of conditions affecting primarily women, are well-documented and constitute a structural inequity in the biomedical research enterprise that has direct clinical consequences for the 190 million people affected by this disease.
If You Recognise Your Body in This
If you are reading this and recognising the description of your own menstrual years — the pain that has always been severe, the days that have always been lost, the pattern that you were told was normal by people who had never asked how severe, the investigation that was never ordered because the symptom was already categorised before anyone measured it — this section is for you.
The symptom pattern of endometriosis is recognisable. Severe dysmenorrhoea that begins before flow onset and does not respond fully to standard analgesics. Deep pain with intercourse. Bowel symptoms — particularly dyschezia or cyclical bowel changes — that are worse with menstruation. Pelvic pain that persists outside of menstruation. Shoulder tip pain during your period. Fatigue that is disproportionate to the blood loss. Infertility or subfertility that has not been explained. Any one of these, combined with severe cyclical pain, constitutes a presentation that demands investigation. Together, they constitute a presentation that should reach a specialist within weeks, not years.
What you need to ask for: transvaginal ultrasound performed by a sonographer or clinician with endometriosis mapping training, explicitly looking for posterior compartment disease — not a standard gynaecological ultrasound that examines the uterus and ovaries but does not systematically assess the pouch of Douglas and uterosacral ligaments. Specialist referral to an endometriosis centre or a gynaecologist with documented endometriosis surgical training. If you have bowel or bladder symptoms, MRI pelvis with bowel preparation before any surgical planning. If your general gynaecologist has told you that your laparoscopy was normal and your pain continues, seek a second opinion from a specialist endometriosis surgeon — the lesions that are missed at non-specialist laparoscopy include the atypical, superficial, red and clear lesions that require specific training to identify. A normal laparoscopy at a non-specialist centre is not the same as a normal laparoscopy at a centre where every morphological subtype is systematically sought and sampled.
The patient organisations — Endometriosis UK, Endometriosis Australia, and the Endometriosis Foundation of America — maintain directories of specialist clinicians and centres that have been identified by both clinical accreditation bodies and by patient communities as practising excision-based surgical management with the training and volume that complex disease requires. Use them. Bring your documented symptom history to every consultation. Ask specifically whether a posterior compartment assessment has been performed. Ask whether histological confirmation of any excised tissue has been requested. Ask whether the surgical approach planned is excision or ablation. These are your clinical rights as a patient, and they are questions that should be routine in every endometriosis consultation. That they are not yet routine is the failure this article is describing.
Your pain has a name.
Your pain has a biology.
Your pain has a treatment.
Endometriosis affects 190 million people worldwide. Its average diagnostic delay is seven to ten years. It produces pain that is, in its most severe expression, among the most disabling experienced by any patient in any specialty. It is routinely dismissed as normal. It is not normal. It is a progressive, inflammatory, surgically and medically treatable disease. The failure to diagnose it is not a reflection of the subtlety of the symptoms. It is a reflection of who has those symptoms and what medicine has decided, culturally, to do with their pain.
Seek specialist evaluation. In the UK, use the BSGE specialist centre directory (bsge.org.uk). In the USA, use EndoFound's specialist directory (endofound.org) and the Nancy's Nook surgeon list. In Australia, use Endometriosis Australia's referral network (endometriosisaustralia.org). Ask specifically for transvaginal ultrasound with posterior compartment mapping. Ask for MRI if bowel or bladder symptoms are present. Ask for referral to a specialist excision surgeon if general gynaecology management has not controlled your symptoms. A laparoscopy that does not systematically look for all lesion morphologies is not a definitive diagnostic laparoscopy. A surgeon who has not specifically trained in endometriosis excision surgery is not the surgeon for complex disease. The diagnosis depends on where you are seen and who is looking — and you have the right to be seen by someone who looks properly.
Dysmenorrhoea requiring prescription analgesia or causing school/work absence: Any woman of reproductive age whose dysmenorrhoea is not controlled by over-the-counter NSAIDs, who has missed school or work due to period pain on more than two occasions, or who describes a progressive deterioration in pain severity over sequential cycles, requires investigation for secondary causes including endometriosis — not reassurance that dysmenorrhoea is normal. Deep dyspareunia with posterior pelvic localisation: Deep pain during intercourse, particularly with positions affecting posterior uterine displacement, that has a cyclical pattern or is associated with other pelvic pain symptoms — immediate posterior compartment assessment and specialist referral. Dyschezia or cyclical bowel symptoms: Painful defaecation or bowel symptoms that are clearly worse with menstruation — immediate endometriosis evaluation, specifically looking for bowel DIE. Shoulder tip pain during menstruation: Referred pain from diaphragmatic irritation via the phrenic nerve during menstruation — pathognomonic of diaphragmatic or thoracic endometriosis when present. Cyclical haemoptysis or pneumothorax: Thoracic endometriosis syndrome until proven otherwise. Cyclical painful swelling in a scar or the umbilicus: Scar endometriosis (particularly in caesarean scar) or umbilical endometriosis — do not excise without considering and investigating this diagnosis. Unexplained subfertility in a woman with any pain symptom: Immediate endometriosis assessment before the 12-month "wait and try" period — the disease does not pause and the fertility window does not wait.
This is the final article in the series The Invisible Catastrophes. Each of the seven conditions described — craniocervical instability, dysautonomia and POTS, tethered cord syndrome, Ehlers-Danlos Syndrome, complex nerve compression, mast cell activation syndrome, and endometriosis — shares a common failure mode: it produces real, measurable, progressive biological disease in a population that medicine has systematically undertreated, misattributed, and dismissed. The failure is not diagnostic in the narrow technical sense — the diagnoses are available, the investigations exist, the treatments are real and effective. The failure is attentional: a failure to look at the right questions, in the right order, with the right degree of seriousness, for the patients to whom medicine has historically paid the least attention. These patients are not rare. Their diagnoses are. The difference between those two facts is the diagnostic delay, and the diagnostic delay is the story of every article in this series.
Endometriosis is not a women's health problem in the sense of being minor, niche, or peripheral to mainstream medicine. It is a women's health problem in the sense of affecting a population that medicine has, for too long, failed to take seriously. 190 million people. Seven to ten years of dismissal. A diagnosis that has existed for a century. A treatment that works. The only thing standing between the patient and the answer was whether anyone bothered to look.
Comments & Responses
Share your experience with endometriosis or pelvic pain